Gastrointestinal Stromal Tumor Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Gastrointestinal Stromal Tumor Market Size Changed, over the years?
The market for gastrointestinal stromal tumor has seen robust growth in the past few years, from $1.28 billion in 2024, it is projected to reach $1.37 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.2%. The growth in the historical period is credited to the heightened awareness and early detection, advent of targeted therapies, improvement of surgical methods, advancement in personalized medicine, and betterment in supportive care.
How Much Will the Gastrointestinal Stromal Tumor Market Be Worth in 2029?
In the upcoming years, the size of the gastrointestinal stromal tumor market is anticipated to experience substantial growth, reaching a valuation of $1.82 billion in 2029 at a CAGR of 7.4%. Factors contributing to growth during this period include persistent efforts in research and drug development, a surge in patient-oriented healthcare, the incorporation of precision medicine into clinical procedures, an increase in the accessibility to targeted therapies, and an expansion in genomic profiling abilities. Noteworthy trends during this forecasted period encompass growing partnerships in research and development, enhancements in diagnostic technologies, cooperative research and clinical trials, a heightened emphasis on early detection and diagnosis, and an exploration of combined therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp
Which is the Largest Company in the Gastrointestinal Stromal Tumor Market?
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.
What Are the Main Market Drivers in the Gastrointestinal Stromal Tumor Industry?
The incidence of stomach cancer is on the rise, which is anticipated to fuel the expansion of the gastrointestinal stromal tumor market. Stomach cancer is characterized by the unchecked growth of malignant cells within the stomach lining. Although gastrointestinal stromal tumors (GISTs) can also occur within the stomach, they should not be conflated with stomach cancer. Interestingly, patients with GISTs have a predisposition to contract extra cancers whenever two separate tumors collide and fuse into one. This includes cancers such as small bowel adenocarcinoma. For example, the American Cancer Society estimates that come January 2024, there will be approximately 26,890 new stomach cancer cases as well as 10,880 deaths in the U.S. alone. This constitutes 1.5% of all new cancer diagnoses for that year. Consequently, the expanding incidence of stomach cancer is propelling the growth of the gastrointestinal stromal tumor market forward. With the surge in demand for precision medicine, the gastrointestinal stromal tumor market is expected to experience significant growth. Precision medicine focuses on individualized healthcare decisions, interventions, and therapies which take into account each patient’s distinct genetic and lifestyle factors. Precision medicine for gastrointestinal stromal tumors involves molecular profiling to pinpoint specific mutations. This helps direct targeted therapies such as imatinib, which enhances the effectiveness of treatment methods and reduces side effects through individualized intervention. For example, the Personalized Medicine Coalition (PMC) reported in February 2023 that personalized medicines were responsible for 35% of the newly approved NMEs in 2021. With an additional 12 new approvals in 2022, personalized medicines have consistently accounted for at least a quarter of all new drug approvals over the past eight years, which is a considerable increase from less than 10% ten years ago. Thus, the burgeoning demand for precision medicine is stimulating the growth of the gastrointestinal stromal tumor market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp
How Is the Gastrointestinal Stromal Tumor Market Segments Structured?
The gastrointestinal stromal tumor market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users
Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies
What Strategic Trends Are Transforming the Gastrointestinal Stromal Tumor Market?
Leading businesses in the gastrointestinal stromal tumor industry are developing novel drugs such as QINLOCK (Ripretinib) to expand their customer reach, accelerate sales, and boost revenue. QINLOCK (Ripretinib) is a prescribed medication for advanced gastrointestinal stromal tumor (GIST). For instance, in January 2024, the US Food and Drug Administration (FDA), an American federal agency, reported that the CDER novel drug approvals increased from 37 in 2022 to 55 in 2023. From these 55 novel drugs approved in 2023, CDER classified 20 of them (or 36%) as first-in-class.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Gastrointestinal Stromal Tumor Market?
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248
This Report Delivers Insight On:
1. How big is the gastrointestinal stromal tumor market, and how is it changing globally?
2. Who are the major companies in the gastrointestinal stromal tumor market, and how are they performing?
3. What are the key opportunities and risks in the gastrointestinal stromal tumor market right now?
4. Which products or customer segments are growing the most in the gastrointestinal stromal tumor market?
5. What factors are helping or slowing down the growth of the gastrointestinal stromal tumor market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
